

## Clean Version of Amended Claims

1 (Currently amended). A process for increasing the optical purity of a mixture of enantiomers of mefloquine, wherein said process comprises using a substantially single enantiomer of a O,O-di-*p*-aroyltartaric acid as a resolving agent.

2 (Currently amended). The process according to claim 1, for preparing a substantially single enantiomer of mefloquine, which proceeds by means of resolution of racemic mefloquine using a substantially single enantiomer of a O,O-di-*p*-aroyltartaric acid as a resolving agent.

3 (Currently amended). The process according to claim 1, wherein the resolving agent is O,O-di-*p*-toluoyl-L-tartaric acid.

4 (Currently amended). The process according to claim 1, wherein the mefloquine is contaminated with *threo*-mefloquine.

5 (Currently amended). The process according to claim 1, which is conducted in a solvent selected from the group consisting of esters, ketones and halogenated solvents.

6 (Currently amended). The process according to claim 1, wherein the resolving agent is present in a sub-stoichiometric quantity, whereby an enantiomer of *erythro*-mefloquine is preferentially obtained.

7 (Currently amended). The process according to claim 6, which is conducted in the presence of an additional chiral or achiral acid.

8 (Currently amended). The process according to claim 1, which further comprises conversion of the salt obtained by the resolution to the free base form of mefloquine or a pharmaceutically acceptable salt thereof.